Sale of Future Royalties - Narrative (Details)	1 Months Ended			3 Months Ended		6 Months Ended			12 Months Ended
Sale of Future Royalties - Narrative (Details)	May 31, 2024 USD ($)	Sep. 30, 2022 USD ($)	Oct. 31, 2021 USD ($)	Dec. 31, 2025 USD ($)	Sep. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2025 USD ($) Milestone	Dec. 31, 2024 USD ($) Milestone	Jan. 01, 2021
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue						$ 53,044,000	$ 50,034,000		$ 234,603,000	$ 91,280,000
Liability related to sale of future royalties				$ 276,528,000		256,493,000			276,528,000	353,426,000
Non-cash interest expense						41,192,000	37,667,000		$ 79,893,000	$ 50,087,000
GSK \| PD-1 (Jemperli/Dostarlimab)
Liabilities Related To Sale Of Future Royalties [Line Items]
Number of milestone \| Milestone									2	2
Collaboration revenue						$ 0			$ 125,000,000	$ 40,000,000
Annual sales milestone threshold										500,000,000
JEMPERLI Royalty Monetization Agreement
Liabilities Related To Sale Of Future Royalties [Line Items]
Net of proceeds			$ 299,500,000
Effective interest rate						34.00%
Non-cash interest expense for the sale of future royalties						$ 41,300,000			81,600,000	49,100,000
Issuance costs related to the sale of future royalties			400,000
JEMPERLI Royalty Monetization Agreement \| Sagard
Liabilities Related To Sale Of Future Royalties [Line Items]
Proceeds from sale of future royalties			250,000,000
Royalties and milestones received						275,900,000
JEMPERLI Royalty Monetization Agreement \| Sagard \| By the end of 2026
Liabilities Related To Sale Of Future Royalties [Line Items]
Royalties and milestones, agreement amount to be received			600,000,000
JEMPERLI Royalty Monetization Agreement \| Sagard \| During 2027
Liabilities Related To Sale Of Future Royalties [Line Items]
Royalties and milestones, agreement amount to be received			675,000,000
JEMPERLI Royalty Monetization Agreement \| GSK
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue						51,200,000	96,000,000	$ 47,400,000	96,000,000	47,400,000
Zejula Royalty Monetization Agreement
Liabilities Related To Sale Of Future Royalties [Line Items]
Net of proceeds		$ 34,800,000
Issuance costs related to the sale of future royalties		200,000
Zejula Royalty Monetization Agreement \| GSK
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue						1,600,000	$ 3,900,000	$ 3,900,000	3,900,000	3,900,000
Settlement agreement rate											0.50%
Non-cash interest expense						$ 200,000			1,900,000	1,000,000
Zejula Royalty Monetization Agreement \| DRI Healthcare Trust
Liabilities Related To Sale Of Future Royalties [Line Items]
Proceeds from sale of future royalties		35,000,000
Liability related to sale of future royalties		$ 35,000,000
Jemperli Royalty Monetization Agreement Amendment 1 \| Sagard
Liabilities Related To Sale Of Future Royalties [Line Items]
Proceeds from sale of future royalties	$ 50,000,000		$ 50,000,000
Issuance costs related to the sale of future royalties	$ 100,000
Jemperli Royalty Monetization Agreement Amendment 1 \| GSK \| PD-1 (Jemperli/Dostarlimab)
Liabilities Related To Sale Of Future Royalties [Line Items]
Annual sales milestone threshold									1,000,000,000
Jemperli Royalty Monetization Agreement, Milestone One \| GSK
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue										75,000,000
Jemperli Royalty Monetization Agreement, Milestone One \| GSK \| PD-1 (Jemperli/Dostarlimab)
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue									50,000,000
Annual sales milestone threshold									750,000,000	250,000,000
Jemperli Royalty Monetization Agreement, Milestone Two \| GSK \| PD-1 (Jemperli/Dostarlimab)
Liabilities Related To Sale Of Future Royalties [Line Items]
Annual sales milestone threshold									1,000,000,000	500,000,000,000
Fourth commercial sales milestone \| GSK \| PD-1 (Jemperli/Dostarlimab)
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue				$ 75,000,000					75,000,000
Third commercial sales milestone \| Sagard \| PD-1 (Jemperli/Dostarlimab)
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue									50,000,000
Third commercial sales milestone \| GSK \| PD-1 (Jemperli/Dostarlimab)
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue					$ 50,000,000				125,000,000	40,000,000
Annual sales milestone threshold									$ 750,000,000	$ 250,000,000